Articles
11.02.2021
EMA Human Medicines

Last month, EMA published its overview of key recommendations for 2020 on the authorisation and safe...

Read more
Articles
26.01.2021
Improving access to innovative medicine in the UK

Following Brexit, the Medicines and Healthcare Regularoty Agency (MHRA) has become the UK's sole bod...

Read more
Articles
04.12.2020
What are the 5 Pricing and Market Access trends th...

Our experts predict the 5 trends they think will dominate the European pricing and market access lan...

Read more
Publications
19.11.2020
ISPO 2020 Developing a sustainable biosimilar

To facilitate biosimilar uptake, several mechanisms aimed at reducing the acquisition cost of biosim...

Read more
Publications
19.11.2020
COVID-19 impact on HTA bodies

HTA bodies and companies within the pharmaceutical industry have been forced to react to unprecedent...

Read more
Publications
19.11.2020
ISPOR 2020 New NICE STA process

This study aimed to assess whether the new process has resulted in changes to outcomes of STAs.

Read more
Articles
09.11.2020
NICE STA Process

A recent study assessed whether this new process has resulted in faster patient access.

Read more
Articles
28.10.2020
EMA regulatory decisions after BREXIT

The UK will continue to adopt decisions taken by the European Commission on the approval of new mark...

Read more
Articles
23.10.2020
Sustainable biosimilar marketplaces

To facilitate biosimilar uptake, several mechanisms encouraging biosimilar uptake have been implemen...

Read more
Articles
12.10.2020
What impact has COVID-19 had on HTA bodies

A survey of employees within pricing and market access n pharma and biotech companies.

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.